Ranolazine Availability in Canada
Ranolazine is NOT currently available for purchase in Canada. While ranolazine (Ranexa) is FDA-approved in the United States and approved in the European Union for chronic stable angina 1, 2, it has not received regulatory approval from Health Canada and therefore cannot be legally purchased or prescribed in Canada.
Key Points About Ranolazine Access
Current Regulatory Status
- FDA-approved in the United States for chronic stable angina as add-on therapy to amlodipine, beta-blockers, or nitrates 1
- Approved in the European Union for use as add-on therapy in patients with stable angina pectoris 2
- Not approved in Canada - no regulatory pathway currently exists for Canadian patients to access this medication through standard channels
Clinical Context from Guidelines
Recent international guidelines recognize ranolazine as a treatment option for chronic coronary syndromes:
- The 2024 ESC Guidelines recommend ranolazine (Class IIa, Level B) as add-on therapy for patients with inadequate symptom control on beta-blockers and/or calcium channel blockers 3
- The 2023 AHA/ACC Guidelines list ranolazine as third-line therapy for microvascular angina, particularly when beta-blockers and calcium channel blockers are insufficient 4
Important Caveat
The 2023 AHA/ACC guidelines specifically note that nicorandil is "currently unavailable in the United States" 4, highlighting how medication availability varies significantly by country. Ranolazine faces the opposite problem in Canada - it's available in the US but not north of the border.
Alternatives for Canadian Patients
For Canadian patients with chronic stable angina requiring additional antianginal therapy beyond first-line agents, available options include:
- Long-acting nitrates
- Combination therapy with beta-blockers and calcium channel blockers
- Nicorandil (if available in Canada)
- Trimetazidine (availability varies by province)
Canadian patients seeking ranolazine would need to work with their healthcare providers to explore alternative evidence-based antianginal therapies that are actually available within the Canadian healthcare system.